1. Home
  2. CHY vs PHAR Comparison

CHY vs PHAR Comparison

Compare CHY & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Convertible and High Income Fund

CHY

Calamos Convertible and High Income Fund

N/A

Current Price

$11.58

Market Cap

960.4M

Sector

Finance

ML Signal

N/A

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

N/A

Current Price

$10.09

Market Cap

793.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHY
PHAR
Founded
2003
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
960.4M
793.4M
IPO Year
2003
2020

Fundamental Metrics

Financial Performance
Metric
CHY
PHAR
Price
$11.58
$10.09
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $34.35
AVG Volume (30 Days)
★ 160.6K
32.7K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
★ 10.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.92
Revenue Next Year
N/A
$8.85
P/E Ratio
★ N/A
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$10.41
$9.62
52 Week High
$13.91
$21.34

Technical Indicators

Market Signals
Indicator
CHY
PHAR
Relative Strength Index (RSI) 33.10 38.55
Support Level $11.35 $9.62
Resistance Level $11.82 $11.60
Average True Range (ATR) 0.25 0.40
MACD -0.06 -0.05
Stochastic Oscillator 19.26 7.95

Price Performance

Historical Comparison
CHY
PHAR

About CHY Calamos Convertible and High Income Fund

Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: